Acquisition of Solta Medical, Inc. by Valeant Pharmaceuticals International, Inc. May Not Be in Shareholders' Best Interests

 Acquisition of Solta Medical, Inc. by Valeant Pharmaceuticals International,
               Inc. May Not Be in Shareholders' Best Interests

PR Newswire

SAN DIEGO and HAYWARD, Calif., Dec. 16, 2013

SAN DIEGO andHAYWARD, Calif., Dec. 16, 2013 /PRNewswire/ -- Shareholder
rights attorneys at Robbins Arroyo LLP are investigating the acquisition of
Solta Medical, Inc. (NASDAQ: SLTM) by Valeant Pharmaceuticals International
Inc. (NYSE: VRX). On December 16, 2013, Valeant Pharmaceuticals announced the
signing of a definitive merger agreement pursuant to which the company will
acquire all outstanding common stock of Solta Medical for $2.92 per share in


Is the Proposed Merger Best for Solta Medical and Its Shareholders?

Robbins Arroyo LLP's investigation focuses on whether the board of directors
at Solta Medical is undertaking a fair process to obtain maximum value and
adequately compensate Solta shareholders in the merger. As an initial matter,
there are currently four analysts with a target price above $3.00, which is
above the offer price, with the Maxim Group maintaining a target price of
$4.00 since May 2, 2013.

Moreover, on November 11, 2013, Solta Medical announced a plan to improve
shareholder value by, among other things, reducing annual expenses by $12
million and generate more than $8 million positive cash flow from operations.
In a press release announcing implementation of the plan, Solta Medical's
Interim CEO, Mark Sieczkarek, commented, "To achieve our 2014 objectives, we
have implemented cost reductions that included a reduction in work force. We
have carefully reviewed the implications of the reductions we have made and
are confident that we will be able to maintain our robust product pipeline and
continue to bring to market innovative aesthetic products. These changes will
improve our financial results next year, while making us a more customer
friendly organization."

Given these facts, Robbins Arroyo LLP is examining the Solta Medical board of
directors' decision to sell the company to Valeant Pharmaceuticals now rather
than allow shareholders to continue to participate in the company's continued
success and future growth prospects, and whether they are seeking to benefit

Solta Medical shareholders have the option to file a class action lawsuit to
ensure the board of directors properly evaluates the proposal to obtain the
best possible price for shareholders and the disclosure of material
information. Solta Medical shareholders interested in information about their
rights and potential remedies can contact attorney Darnell R. Donahue at (800)
350-6003,, or via the shareholder information form
on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation
and shareholder rights law. The law firm represents individual and
institutional investors in shareholder derivative and securities class action
lawsuits, and has helped its clients realize more than $1 billion of value for
themselves and the companies in which they have invested.

Attorney Advertising.Past results do not guarantee a similar outcome.

Darnell R. Donahue
Robbins Arroyo LLP
(619) 525-3990 or Toll Free (800) 350-6003

SOURCE Robbins Arroyo LLP

Press spacebar to pause and continue. Press esc to stop.